GRANIX® (tbo-filgrastim) injection, for subcutaneous use

Initial U.S. Approval: 2012

**HIGHLIGHTS OF PRESCRIBING INFORMATION**

These highlights do not include all the information needed to use GRANIX safely and effectively. See full prescribing information for GRANIX.

**GRANIX® (tbo-filgrastim) injection, for subcutaneous use**

**Indications and Usage (1)**

**Recent Major Changes**

- Indications and Usage (1) 07/2018
- Dosage and Administration (2.2) 07/2018
- Warnings and Precautions, Leukocytosis (5.8) 07/2018
- Warnings and Precautions, Simultaneous Use with Chemotherapy and Radiation Therapy Not Recommended (5.9) 07/2018
- Warnings and Precautions, Nuclear Imaging (5.10) 07/2018
- Warnings and Precautions, Aortitis (5.11) 07/2018

**INDICATIONS AND USAGE**

GRANIX (tbo-filgrastim) is a leukocyte growth factor indicated in adult and pediatric patients 1 month and older for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. (1)

**Dosage and Administration**

- Recommended dose: 5 mcg/kg per day administered as a subcutaneous injection.
- Administer the first dose no earlier than 24 hours following myelosuppressive chemotherapy. Do not administer within 24 hours prior to chemotherapy (2.1)

**DOSAGE FORMS AND STRENGTHS**

- Prefilled Syringe
  - Injection: 300 mcg/0.5 mL solution in single-dose prefilled syringe (3)
  - Injection: 480 mcg/0.8 mL solution in single-dose prefilled syringe (3)
  - Vial
    - Injection: 300 mcg/1 mL solution in single-dose vials (3)
    - Injection: 480 mcg/1.6 mL solution in single-dose vials (3)

**FULL PRESCRIBING INFORMATION: CONTENTS**

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Dosage

2.2 General Considerations for Administration

2.3 Instructions for Use of the Safety Needle Guard Device by Healthcare Professionals

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Spleenic Rupture

5.2 Acute Respiratory Distress Syndrome (ARDS)

5.3 Allergic Reactions

5.4 Use in Patients with Sickle Cell Disease

5.5 Glomerulonephritis

5.6 Capillary Leak Syndrome

5.7 Potential for Tumor Growth Stimulatory Effects on Malignant Cells

5.8 Leukocytosis

5.9 Simultaneous Use with Chemotherapy and Radiation Therapy Not Recommended

5.10 Nuclear Imaging

5.11 Aortitis

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

6.2 Immunogenicity

6.3 Postmarketing Experience

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

Patient Information

Instructions for Use

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

17 PATIENT COUNSELING INFORMATION

Patient Information

Instructions for Use

Full prescribing information: contents

1 INDICATIONS AND USAGE

GRANIX is indicated to reduce the duration of severe neutropenia in adult and pediatric patients 1 month and older with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. (1)

2 DOSAGE AND ADMINISTRATION

2.1 Dosage

The recommended dose of GRANIX is 5 mcg/kg per day administered as a subcutaneous injection. Administer the first dose of GRANIX no earlier than 24 hours following myelosuppressive chemotherapy. Do not administer GRANIX within 24 hours prior to chemotherapy. Daily dosing with GRANIX should continue until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range. Monitor complete blood count (CBC) prior to chemotherapy and twice per week until recovery.

2.2 General Considerations for Administration

GRANIX may be administered by either a healthcare professional, a patient or caregiver. Before a decision is made to allow GRANIX to be administered by a patient or caregiver, ensure that the patient is an appropriate candidate for self-administration or administration by a caregiver. Proper training on storage, preparation, and administration technique should be provided. If a patient or caregiver is not an appropriate candidate for any reason, then in such patients, GRANIX should be administered by a healthcare professional.

Dispense only the prefilled syringe without a safety needle guard device to patient or caregiver. Instruct patients and caregivers to follow the Instructions for Use provided with the GRANIX prefilled syringe to properly administer an injection after training by a healthcare professional.

Visually inspect parenteral drug products for particulate matter and discoloration prior to administration. Do not administer GRANIX if discoloration or particulates are observed.

1 The prefilled syringe and vial are for single-dose only. Discard unused portions. GRANIX and all its components are not made with natural rubber latex.

Recommended sites for subcutaneous GRANIX injections include the abdomen (except for the two-inch area around the navel), the front of the middle thighs, the upper outer areas of the buttocks, or the upper back portion of the upper arms. The injection site should be varied daily. GRANIX should not be injected into an area that is tender, red, bruised or hard, or that has scars or stretch marks.

*Sections or subsections omitted from the full prescribing information are not listed.
GRANIX® (tbo-filgrastim) injection

2.3 Instructions for Use of the Safety Needle Guard Device by Healthcare Professionals

Hold the syringe assembly by the open sides of the device and remove the needle shield.

Expel any extra volume depending on dose needed.

Inject GRANIX subcutaneously as recommended [see Dosage and Administration (2.2)]. Push the plunger as far as it will go to inject all the medication. Injection of the entire prefilled syringe contents is necessary to activate the needle guard.

With the plunger still pressed all the way down, remove the needle from the skin.

Slowly let go of the plunger and allow the empty syringe to move up inside the device until the entire needle is guarded.

Discard the syringe assembly in approved containers.

3 DOSAGE FORMS AND STRENGTHS

GRANIX is a clear, colorless, preservative-free solution available as:

- Prefilled Syringe:
  - Injection: 480 mcg/0.8 mL (600 mcg/mL) solution in single-dose prefilled syringe
  - Injection: 300 mcg/0.5 mL (600 mcg/mL) solution in single-dose prefilled syringe
  - Injection: 480 mcg/0.8 mL (600 mcg/mL) solution in single-dose prefilled syringe

4 CONTRAINDICATIONS

GRANIX is contraindicated in patients with a history of serious allergic reactions to filgrastim products or pegfilgrastim.

5 WARNINGS AND PRECAUTIONS

5.1 Fatal Splenic Rupture

Splenic rupture, including fatal cases, can occur following administration of filgrastim products. Evaluate patients who report upper abdominal or shoulder pain for an enlarged spleen or splenic rupture. Discontinue GRANIX if splenic rupture is suspected or confirmed.

5.2 Acute Respiratory Distress Syndrome (ARDS)

Acute respiratory distress syndrome (ARDS) can occur in patients receiving filgrastim products. Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving GRANIX, for ARDS. Discontinue GRANIX in patients with ARDS.

5.3 Serious Allergic Reactions

Serious allergic reactions, including anaphylaxis, can occur in patients receiving GRANIX. Reactions can occur on initial exposure. The administration of antihistamines, steroids, bronchodilators, and/or epinephrine may reduce the severity of the reactions. Permanently discontinue GRANIX in patients with serious allergic reactions. Do not administer GRANIX to patients with a history of serious allergic reactions to filgrastim or pegfilgrastim.

5.4 Sickle Cell Disorders

Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving filgrastim products. Discontinue GRANIX if sickle cell crisis occurs.

5.5 Glomerulonephritis

Glomerulonephritis can occur in patients receiving filgrastim products. The diagnoses were based on azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy. Generally, events of glomerulonephritis resolved after dose reduction or discontinuation of the filgrastim product. If glomerulonephritis is suspected, evaluate for cause. If causality is likely, consider dose-reduction or interruption of GRANIX.

5.6 Capillary Leak Syndrome

Capillary leak syndrome (CLS) can occur in patients receiving filgrastim products and is characterized by hypotension, hypoalbuminemia, edema and hemococoncentration. Episodes vary in frequency, severity and may be life-threatening if treatment is delayed. Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care.

5.7 Potential for Tumor Growth Stimulatory Effects on Malignant Cells

The granulocyte colony-stimulating factor (G-CSF) receptor through which GRANIX acts has been found on tumor cell lines. The possibility that GRANIX acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which GRANIX is not approved, cannot be excluded.

5.8 Leukocytosis

White blood cell counts of 100,000/mm³ or greater were observed in approximately 2% of patients receiving filgrastim products at dosages above 5 mcg/kg/day. In patients with cancer receiving GRANIX as an adjunct to myelosuppressive chemotherapy, to avoid the potential risks of excessive leukocytosis, it is recommended that GRANIX therapy be discontinued if the ANC surpasses 10,000/mm³ after the chemotherapy-induced ANC nadir has occurred. Monitor CBCs at least twice weekly during therapy.

5.9 Simultaneous Use with Chemotherapy and Radiation Therapy Not Recommended

The safety and efficacy of filgrastim products, including GRANIX, given simultaneously with cytotoxic chemotherapy have not been established. Because of the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy, do not use GRANIX in the period 24 hours before through 24 hours after the administration of cytotoxic chemotherapy [see Dosage and Administration (2.2)].

5.10 Nuclear Imaging

Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone-imaging changes. Consider this when interpreting bone-imaging results.

5.11 Aortitis

Aortitis has been reported in patients receiving another filgrastim product. It may occur as early as the first week after start of therapy. Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count). Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue GRANIX if aortitis is suspected.

6 ADVERSE REACTIONS

The following potential serious adverse reactions are discussed in greater detail in other sections of the labeling:

- Fatal Splenic Rupture [see Warnings and Precautions (5.1)]
- Acute Respiratory Distress Syndrome [see Warnings and Precautions (5.2)]
- Serious Allergic Reactions [see Warnings and Precautions (5.3)]
- Sickle Cell Disorders [see Warnings and Precautions (5.4)]
- Glomerulonephritis [see Warnings and Precautions (5.5)]
- Capillary Leak Syndrome [see Warnings and Precautions (5.6)]
- Potential for Tumor Growth Stimulatory Effects on Malignant Cells [see Warnings and Precautions (5.7)]
- Leukocytosis [see Warnings and Precautions (5.8)]
- Simultaneous Use with Chemotherapy and Radiation Therapy Not Recommended [see Warnings and Precautions (5.9)]
- Aortitis [see Warnings and Precautions (5.11)]
6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Adverse Reactions in Adult Patients

GRANIX clinical trials safety data are based upon the results of three randomized clinical trials in patients receiving myeloablative chemotherapy for breast cancer (N=348), lung cancer (N=240) and non-Hodgkin’s lymphoma (N=92). In the breast cancer study, 99% of patients were female, the median age was 50 years, and 86% of patients were Caucasian. In the lung cancer study, 80% of patients were male, the median age was 58 years, and 95% of patients were Caucasian. In the non-Hodgkin’s lymphoma study, 52% of patients were male, the median age was 55 years, and 88% of patients were Caucasian. In all three studies a placebo (Cycle 1 of the breast cancer study only) or a non-US-approved filgrastim product were used as controls.

Both the US-approved and the non-US-approved filgrastim product were administered at 5 mcg/kg subcutaneously once daily beginning one day after chemotherapy for at least five days and continued to a maximum of 14 days or until an ANC of ≥10,000 x 10^6/L after nadir was reached.

Bone pain was the most frequent treatment-emergent adverse reaction that occurred in at least 1% of patients treated with GRANIX at the recommended dose and was numerically twice more frequent than in the placebo group. The overall incidence of bone pain in Cycle 1 of treatment was 3.4% (3.4% GRANIX, 1.4% placebo, 7.5% non-US-approved filgrastim product).

Leukocytosis

In clinical studies, leukocytosis (WBC counts > 100,000 x 10^6/L) was observed in less than 1% patients with non-myeloid malignancies receiving GRANIX. No complications attributable to leukocytosis were reported in clinical studies.

Additional Adverse Reactions

Other adverse reactions known to occur following administration of filgrastim products include myalgia, headache, vomiting, cutaneous vasculitis and thrombocytopenia.

Adverse Reactions in Pediatric Patients

GRANIX clinical trials safety data in pediatric patients are based upon the results of one single-arm clinical trial in 50 pediatric patients who received myelosuppressive chemotherapy for treatment of a solid tumors without marrow involvement (see Use in Special Patient Populations (8.4)). In this study, GRANIX was administered at 5 mcg/kg subcutaneously once daily beginning one day after chemotherapy. The most common (>5%) adverse reactions included thrombocytopenia (34%), pyrexia (8%), pain in extremity (6%), headache (6%) and diarrhea (6%).

As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay, and the observed incidence of antibody positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, underlying disease, and underlying disease. For these reasons, comparison of the incidence of antibodies to GRANIX with the incidence of antibodies to other products may be misleading.

Binding antibodies to GRANIX were detected using a validated bridging immunoassay. Anti-drug antibodies to tbo-filgrastim occurred in 1.4% of ≥486 adult and pediatric patients. None of these patients had cross-reactive antibodies to the native G-CSF. All antibody responses were transient and of low titers.

6.3 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of GRANIX. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Sweet's syndrome (acute febrile neutrophilic dermatosis), asthenia, diarrhea, and fatigue

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

The limited published data on filgrastim product use during pregnancy are insufficient to inform a drug-associated risk. In animal reproduction studies, administration of tbo-filgrastim to pregnant rabbits during the period of organogenesis resulted in increased spontaneous abortions and malformations at the dose levels of 100 mcg/kg/day, which was 24% to 60% of the maternal weight. These doses are approximately 18 times the systemic exposure (AUC) of approximately 50-90 times the exposures observed in patients treated with the clinical tbo-filgrastim dose of 5 mcg/kg/day.

8.2 Lactation

No data are available regarding the presence of tbo-filgrastim in human milk, the effects of the drug on the breast-fed child, or the effects of the drug on milk production.

8.3 Pediatric Use

The safety and effectiveness of GRANIX have been established for pediatric patients 1 month to < 17 years old (no data for the age group < 1 month old). Use of GRANIX in these age groups is supported by evidence from adequate and well-controlled studies of GRANIX in adults (see Clinical Studies (14)) with additional safety and pharmacokinetics data from a single-arm trial of 50 pediatric patients with solid tumors treated with GRANIX for chemotherapy-induced neutropenia. The 50 pediatric patients had a median age of 9.2 years (range, 1.4-15.9 years); 2 were infants (1 month to < 2 years old), 30 were children (2 to < 12 years old), and 18 were adolescents (12 to < 17 years old). The pharmacokinetics and safety profile of GRANIX in the pediatric population were similar to those seen in adults (see Adverse Reactions (6.1), Clinical Pharmacology (12.3)).

8.4 Pediatric Use

Among 677 cancer patients enrolled in clinical trials of GRANIX, a total of 111 patients were 65 years of age and older, and 14 patients were 75 years and older. No overall differences in safety or effectiveness were observed between patients age 65 and older and younger patients.

11 DESCRIPTION

GRANIX (tbo-filgrastim) is a non-glycosylated recombinant methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF) manufactured by recombinant DNA technology using the bacterium strain E. coli K802. It has a molecular weight of approximately 18.8 kDa and is composed of 175 amino acids. The endogenous human G-CSF is glycosylated and does not have the additional methionine amino acid residue in its NH2 terminal end.

The product is a sterile, clear, colorless, preservative-free solution containing tbo-filgrastim, glacial acetic acid, sorbitol, polysorbate 80, sodium hydroxide, and Water for Injection. The product is available in single-dose prefilled syringes that contain either 300 mcg or 480 mcg of tbo-filgrastim at a fill volume of 0.5 mL or 0.8 mL, respectively and single-dose vials that contain either 300 mcg or 480 mcg of tbo-filgrastim at a fill volume of 1 mL or 1.6 mL, respectively. See table below for product composition of each presentation.

<table>
<thead>
<tr>
<th>Product Composition</th>
<th>300 mcg</th>
<th>480 mcg</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5 mL Syringe</td>
<td>480 mcg</td>
<td>0.8 mL Syringe</td>
</tr>
<tr>
<td>Glacial Acetic Acid</td>
<td>0.3 mg</td>
<td>0.48 mg</td>
</tr>
<tr>
<td>Polysorbate 80</td>
<td>0.0275 mg</td>
<td>0.044 mg</td>
</tr>
<tr>
<td>Sorbitol</td>
<td>25 mg</td>
<td>40 mg</td>
</tr>
<tr>
<td>Sodium Hydroxide</td>
<td>q.s. to pH 4</td>
<td>q.s. to pH 4</td>
</tr>
<tr>
<td>Water for Injection</td>
<td>q.s. to 0.5 mL</td>
<td>q.s. to 0.8 mL</td>
</tr>
</tbody>
</table>

q.s. = quantity sufficient to make pH 4.2

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

GRANIX is a human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. Tbo-filgrastim binds to G-CSF receptors and stimulates proliferation of neutrophils. G-CSF is known to stimulate differentiation and some end-cell functional activation, which increases neutrophils numbers and activity.

12.2 Pharmacodynamics

The time to the maximum ANC level was between 3 to 5 days and returned to baseline by 21 days following completion of chemotherapy. Doubling the tbo-filgrastim subcutaneous dose from 5 mcg/kg to 10 mcg/kg resulted in a 16% to 19% increase in the maximum ANC level and a 33% to 38% increase in the area under the effect curve for ANC.

Cardiac Electrophysiology

At an intravenous dose of 5 mcg/kg, tbo-filgrastim did not prolong the QT interval to any clinically relevant extent.

12.3 Pharmacokinetics

Tbo-filgrastim exhibits nonlinear pharmacokinetics. Increasing the dose of subcutaneous GRANIX from 5 to 10 mcg/kg resulted in an approximate 2.5-fold increase in the maximum serum concentration (Cmax) and 3.0-fold increase in the area under the curve (AUC). In adult patients enrolled across three studies, subcutaneous GRANIX 5 mcg/kg resulted in median time to maximal serum tbo-filgrastim concentrations (Tmax) within 4 to 6 hours. Geometric mean [coefficient of variation (CV%)] serum Cmax was 20 to 31 ng/mL [24% to 65%] within 4 to 6 hours. Geometric mean serum tbo-filgrastim area under the curve (AUC0-12h) ranged from 151 to 227 ng·h/mL [24% to 60%]. No accumulation in serum tbo-filgrastim concentrations was observed after multiple dosing.

Absorption

The absolute bioavailability of 5 mcg/kg subcutaneous tbo-filgrastim was 33%.

Metabolism/Elimination

The elimination half-life of tbo-filgrastim (5 mcg/kg sc) was 3.5 to 3.8 hours.
GRANIX® (tbo-filgrastim) injection

Specific Populations
No sex-related differences were observed.

Pediatric Patients:
The geometric mean [coefficient of variation (CV%)] of CVmax was 18 ng/mL (56%) and AUC0-12h was 130 ng*h/mL (52%) following subcutaneous administration of GRANIX 5 mcg/kg in 49 pediatric patients (1.4 to 15.9 years) after chemotherapy. No clinically relevant differences in the pharmacokinetics of GRANIX were observed between infants, children and adolescents.

Patients with Renal or Hepatic Impairment:
Mild renal impairment (creatinine clearance 60 to 89 mL/min by Cockcroft-Gault) had no effect on tbo-filgrastim pharmacokinetics. The pharmacokinetics in patients with moderate and severe renal impairment has not been studied. The pharmacokinetics in patients with hepatic impairment has not been studied.

13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenicity and genetic toxicology studies have not been conducted with tbo-filgrastim.

A fertility study was not conducted with tbo-filgrastim. Toxicology studies of up to 26 weeks in rats or monkeys did not reveal findings in male or female reproductive organs that would suggest impairment of fertility.

14 CLINICAL STUDIES
The efficacy of GRANIX was evaluated in a multinational, multicenter, randomized and controlled Phase 3 study in 348 chemotherapy-naive patients with high-risk stage II, stage III, or stage IV breast cancer receiving doxorubicin (60 mg/m2) and docetaxel (75 mg/m2) comparing GRANIX to placebo and a non-US-approved filgrastim product as controls. The median age of the patients was 50 years (range 25 to 75 years) with 99% female and 86% Caucasian. GRANIX, placebo, and the non-US-approved filgrastim product were administered at 5 mcg/kg subcutaneously once daily beginning one day after chemotherapy for at least five days and continued to a maximum of 14 days or until an ANC of ≤10,000 x 10/L after nadir was reached.

GRANIX was superior to placebo in duration of severe neutropenia (DSN) with a statistically significant reduction in DSN (1.1 days vs. 3.8 days, p < 0.0001). GRANIX was superior to placebo in duration of severe neutropenia (DSN) with a statistically significant reduction in DSN (1.1 days vs. 3.8 days, p < 0.0001). GRANIX was superior to placebo in duration of severe neutropenia (DSN) with a statistically significant reduction in DSN (1.1 days vs. 3.8 days, p < 0.0001). GRANIX was superior to placebo in duration of severe neutropenia (DSN) with a statistically significant reduction in DSN (1.1 days vs. 3.8 days, p < 0.0001). GRANIX was superior to placebo in duration of severe neutropenia (DSN) with a statistically significant reduction in DSN (1.1 days vs. 3.8 days, p < 0.0001). GRANIX was superior to placebo in duration of severe neutropenia (DSN) with a statistically significant reduction in DSN (1.1 days vs. 3.8 days, p < 0.0001). GRANIX was superior to placebo in duration of severe neutropenia (DSN) with a statistically significant reduction in DSN (1.1 days vs. 3.8 days, p < 0.0001). GRANIX was superior to placebo in duration of severe neutropenia (DSN) with a statistically significant reduction in DSN (1.1 days vs. 3.8 days, p < 0.0001).
What is GRANIX? GRANIX is a prescription medicine:
• used in people with certain types of cancer (non-myeloid malignancies), who are receiving chemotherapy that affects the bone marrow
• given to help decrease the length of time that the number of certain white blood cells (neutrophils) are very low (severe neutropenia). Neutrophils are white blood cells that are important in fighting bacterial infections.
It is not known if GRANIX is safe and effective in children younger than 1 month of age.

Do not take GRANIX if you have had a serious allergic reaction to filgrastim products or pegfilgrastim products.

Before you receive GRANIX, tell your healthcare provider about all of your medical conditions, including if you:
• have a sickle cell disorder
• have kidney problems
• plan to have bone scans or tests
• are pregnant or plan to become pregnant. It is not known if GRANIX will harm your unborn baby. You should not become pregnant during treatment with GRANIX.
• are breastfeeding or plan to breastfeed. It is not known if GRANIX passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive GRANIX?
• GRANIX is given by an injection under your skin (subcutaneous) by a healthcare provider. Your healthcare provider may decide injections can be given at home by you or your caregiver. If GRANIX is given at home, see the detailed “Instructions for Use” that comes with your GRANIX for information on how to prepare and inject a dose of GRANIX.
• Your healthcare provider will show you and your caregiver how to prepare and inject GRANIX before you use it.
• Your healthcare provider will tell you how much GRANIX to inject and when to inject it. Do not stop using GRANIX or change your dose unless your healthcare provider tells you to.
• GRANIX injections are usually given 1 time each day until your white blood cell count returns to normal.
• Your first dose of GRANIX is given at least 24 hours after you receive your chemotherapy.
• Do not inject GRANIX within 24 hours before your next dose of chemotherapy.
• Your healthcare provider will test your blood before your chemotherapy and during treatment with GRANIX.
• If GRANIX gets on your skin or your caregiver’s skin, wash the area with soap and water.
• If GRANIX gets in your eyes or your caregiver’s eyes, flush the eyes well with water.

What are the possible side effects of GRANIX? GRANIX can cause serious side effects, including:
• Spleen rupture. Your spleen may become enlarged and can rupture. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in your left upper stomach (abdomen)-area or your left shoulder during treatment with GRANIX.
• A serious lung problem called acute respiratory distress syndrome (ARDS). Call your healthcare provider or get emergency medical help right away if you have shortness of breath with or without fever, trouble breathing, or a fast rate of breathing.

• Serious allergic reactions. GRANIX can cause serious allergic reactions. These reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate, and sweating. If you have any of these symptoms, stop using GRANIX and call your healthcare provider or get emergency help right away.
• Sickle cell crisis. You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder and use GRANIX. Call your healthcare provider right away if you have symptoms of sickle cell crisis such as pain or difficulty breathing.
• Kidney injury (glomerulonephritis). GRANIX can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms:
  ◦ swelling of your face or ankles
  ◦ blood in your urine or dark colored urine
  ◦ you urinate less than usual
• Capillary Leak Syndrome. GRANIX can cause fluid to leak from blood vessels into your body’s tissues. This condition is called “Capillary Leak Syndrome” (CLS). CLS can quickly cause you to have symptoms that may become life-threatening. Get emergency medical help right away if you develop any of the following symptoms:
  ◦ swelling of your face or ankles
  ◦ trouble breathing
  ◦ swelling of your stomach-area (abdomen) and feeling of fullness
  ◦ dizziness or feeling faint
  ◦ a general feeling of tiredness
• Inflammation of the aorta (aortitis). Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported in patients who received another filgrastim product. Symptoms may include fever, abdominal pain, feeling tired, and back pain. Call your healthcare provider if you experience these symptoms.
Your healthcare provider may decrease your dose, temporarily stop, or permanently stop treatment with GRANIX if you have certain side effects.

The most common side effect of GRANIX is bone pain. Other possible side effects of other filgrastim products that may also happen with GRANIX may include muscle aches (myalgia), headache, weakness, diarrhea, fatigue, vomiting, inflamed blood vessels in the skin (cutaneous vasculitis), low platelet count (thrombocytopenia), and Sweet’s syndrome (a rare skin condition that mainly includes fever and painful skin lesions that appear mostly on the arms, neck, head and trunk). These are not all of the possible side effects of GRANIX. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store GRANIX?
• Store GRANIX in the refrigerator between 36°F to 46°F (2°C to 8°C).
• Keep GRANIX away from light to protect it. If your GRANIX is left in the refrigerator for more than 5 days, return GRANIX back to the refrigerator. Throw away (dispose of) GRANIX that has been left at room temperature for more than 5 days.
• Take GRANIX out of the refrigerator 30 minutes before use and allow it to reach room temperature before preparing an injection.
• GRANIX can be left at room temperature for up to 5 days. If not used within 5 days, return GRANIX back to the refrigerator. Throw away (dispose of) GRANIX that has been left at room temperature for more than 5 days.
• Do not shake.
• After you inject your dose, throw away (dispose of) any unused GRANIX left in the syringe or vial. Do not save unused GRANIX in the syringe or the vial for later use.

Keep GRANIX and all medicines out of the reach of children.
GRANIX® (tbo-filgrastim) injection

General information about the safe and effective use of GRANIX
Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflets. Do not use GRANIX for a condition for which it was not prescribed. Do not give GRANIX to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about GRANIX that is written for health professionals.

What are the ingredients in GRANIX?
Active ingredient: tbo-filgrastim
Inactive ingredients: glacial acetic acid, polysorbate 80, sorbitol, sodium hydroxide, and Water for Injection

Manufactured by: Distributed by:
Sicor Biotech UAB Teva Pharmaceuticals USA, Inc.
Vilnius, Lithuania North Wales, PA 19454
U.S. License No. 1803 Product of Israel

This Patient Information has been approved by the U.S. Food and Drug Administration Revised: 07/2018

Instructions for Use
GRANIX (GRAN-icks)
(tbo-filgrastim)
for subcutaneous injection
Single-Dose Vial

Important:
Read the Prescribing information and Patient Package insert for important information about GRANIX.

Before you use a GRANIX vial, read this important information:
• GRANIX vial is supplied as either 300 mcg in 1.0 mL solution, or 480 mcg of tbo-filgrastim in 1.6 mL solution. Your healthcare provider will determine which strength of GRANIX to prescribe for you. Your healthcare provider will prescribe the correct number of vials, and the dose in milliliters (mL) that you will need to inject based on your body weight.
• When you receive your vials of GRANIX at the pharmacy, check the label to be sure that the dose strength on the vial matches the dose strength that your healthcare provider prescribed for you. If you are not sure, ask your pharmacist.
• If you are told that more than 1 injection is needed for each dose of GRANIX, the total dose should be divided into two equal parts. Each of the two parts of your dose should be drawn from a separate vial.
• Your healthcare provider will show you how to measure the correct dose of GRANIX before you try to inject it for the first time. This dose will be measured in milliliters (mL).

How to store your GRANIX vial
• Store GRANIX in the refrigerator between 36°F to 46°F (2°C to 8°C).
• Keep GRANIX vials away from light to protect it. If your GRANIX vial comes in a carton, keep it in the carton until you are ready to use it to protect from light.
• Do not freeze.
• Take GRANIX out of the refrigerator 30 minutes before use and allow it to reach room temperature before preparing an injection.
• GRANIX vials can be left at room temperature for a single period of up to 5 days, and if not used can be returned to the refrigerator to use later. Throw away (dispose of) any GRANIX vials that have been left at room temperature for more than 5 days.
• After you inject your dose, properly dispose of any unused GRANIX left in the vial. Do not save unused GRANIX for later use.

Keep GRANIX and all medicines out of the reach of children.

Using your vial
• It is important that you do not try to give the injection unless you or your caregiver has received training from your healthcare provider.
• Make sure that the name GRANIX appears on the carton and vial label.
• Check the label and the expiration date on the side of the carton.
• Do not use a vial after the expiration date on the label.
• Do not shake the vial.
• Do not use the vial if the medicine is cloudy or discolored, or contains flakes or particles.
• Do not inject your first dose of GRANIX until at least 24 hours after you receive your chemotherapy. You should continue to receive GRANIX daily until your healthcare provider tells you that your white blood cell count has returned to normal. Do not inject GRANIX less than 24 hours before your next dose of chemotherapy. Call your healthcare provider if you have any questions.

FOLLOW THE STEPS BELOW FOR EACH DAY OF DOERING

STEP 1: Prepare
Step 1A: Remove GRANIX from the refrigerator
Take the GRANIX® (tbo-filgrastim) carton out of the refrigerator.
Open the carton by lifting the lid and breaking the seal.
Step 1B: Check the label and the expiration date on the carton
• Check to make sure GRANIX® (tbo-filgrastim) is listed on the carton.
• Do not use if the expiration date on the carton has passed.
Remove the number of vials needed for the daily dose.
Return the carton containing any unused vials to the refrigerator.
Step 1C: Wait 30 minutes for the vials to reach room temperature.
Place the vials of GRANIX on a clean, well-lit flat work surface for about 30 minutes to warm to room temperature. This will help to provide a more comfortable injection.
• Do not try to warm the vial by using a heat source such as hot water or microwave.
• Protect the vial from light.
• Do not shake the vial.
• Use a vial only 1 time.

Step 10: Inspect the vial
Hold each vial and check to make sure it is not damaged. Inspect the medicine in the vial. Make sure the medicine in the vial is clear and colorless.
• Check to make sure GRANIX is listed on the vial label.
• Do not use the vial if:
  ◦ The medicine is cloudy or discolored, or contains flakes or particles.
  ◦ The expiration date on the vial label has passed.
• In these cases, use a new vial and call your healthcare provider.

Step 1E: Gather the following supplies needed for each injection and place them on your clean work surface (Figure A):
• 1 GRANIX vial
• 1 disposable syringe and needles
• 2 alcohol swabs
• 1 cotton balls or gauze pad(s)
• 1 adhesive Bandage(s), if needed
• 1 sharps disposal container

Vial

Disposabe Syringe

Needle

Dose Scale

Label

Plunger

Thumb Pad

Syringe Body

Needle Cap

Gauze Pad or Cotton Ball

Alcohol Swab

Sharps Container

FIGURE A
GRANIX® (tbo-filgrastim) injection

- Only use disposable syringes and needles that your healthcare provider prescribes.
- Only use the syringes and needles 1 time. Throw away (dispose of) any used syringes and needles in a sharps disposal container.
- You should only use syringes that are marked in tenths of milliliters (mL).
- Your healthcare provider will show you how to measure the correct dose of GRANIX. This dose will be measured in milliliters (mL).

**Step 1F: Wash your hands.**
When ready to inject, wash your hands well with soap and water, and dry with a clean towel.

**STEP 2: Get ready**

**Step 2A: Take the cap off the vial (Figure B).** Clean the rubber stopper with 1 alcohol swab.

**FIGURE B**

**Step 2B: Check the packaging for the syringe and needle.** If the packaging has been open or damaged, do not use that syringe and needle. Throw away (dispose of) that syringe and needle in your sharps disposal container.

**Step 2C: Hold the syringe by the barrel with the needle cap pointing up. Carefully pull the needle cap straight off and away from your body (Figure C).**

**Important:** Throw away (Dispose of) the needle cap.

**FIGURE C**

**Step 2D: Keep the vial on the flat work surface and insert the needle straight down through the rubber stopper on top of the vial. **Do not** insert the needle through the rubber stopper more than 1 time (Figure D).**

**Step 2E: Push the plunger down and inject all the air from the syringe into the vial of GRANIX (Figure D).**

**FIGURE D**

**Step 2F: Keep the needle in the vial and turn the vial upside down. Make sure that the GRANIX liquid is covering the tip of the needle (Figure E).**

**FIGURE E**

**Step 2G: Keep the vial upside down and slowly pull back on the plunger to fill the syringe barrel with GRANIX to the correct marking amount (mL) of medicine that matches the dose your healthcare provider prescribed.**

**Step 2H: Keep the needle in the vial and check for air bubbles in the syringe.** If there are air bubbles, gently tap the syringe barrel with your finger until the air bubbles rise to the top. Slowly push the plunger up to push the air bubbles out of the syringe (Figure F).

**FIGURE F**

**Step 2I: Keep the tip of the needle in the liquid and pull the plunger back to the number on the syringe barrel that matches your dose. Check again for air bubbles. The air in the syringe will not hurt you, but too large an air bubble can reduce your dose of GRANIX. If there are still air bubbles, repeat the steps above to remove them.**

**Step 2J: Check again to make sure that you have the correct dose in the syringe. It is important that you use the exact dose prescribed by your healthcare provider. Do not remove the needle from the vial. Lay the vial down on its side with the needle still in the vial while you prepare the injection site (Figure G).**

**FIGURE G**

**STEP 3 – Select and prepare the injection site**

**Step 3A: Choose an injection site (Figure H)**
You can use:
- **Stomach-area (abdomen):** Except for a 2-inch area around the navel (belly button)
- **Thighs:** Top or middle area of thighs
- **Arms:** Fleshy areas on upper, back part of the arm (only if someone else is giving you the injection)
- **Upper outer area of your buttocks:** Fleshy areas around the back of the upper hips and upper sides of the buttocks (only if someone else is giving you the injection).
- **If 2 injections will be performed, then the second injection should be at least 1 inch away from the first injection.**
Do not inject into areas that are tender, red, bruised, hard, or have scars or stretch marks.

**Important:**
You should select a different injection site each time you give yourself an injection. If you want to use the same injection site for a dose requiring 2 injections, make sure the second injection site is at least 1 inch away from the first injection site.

**Step 3B:** Clean the injection site using a new alcohol swab (Figure I).
Allow site to dry for 5-10 seconds to avoid stinging.
If giving 2 injections, then the distance between the 2 injection sites should be at least 1 inch apart.

**FIGURE H**

**Step 4A:** Remove the prepared syringe and needle from the vial.
**Step 4B:** With your other hand, pinch the skin around the injection site to create a firm surface (Figure J).

**Important:** Keep skin pinched while inserting the needle.

**Step 4C:** Insert the needle at a 45 to 90 degree angle (Figure K)
• Hold the body of the syringe between your thumb and index finger.
• Use a quick motion to fully insert the needle straight into the pinched skin at a 45 to 90 degree angle.
• When the needle is inserted, you can release the pinched skin.

**FIGURE J**

**Step 4D:** Push the plunger down to inject all of the GRANIX (Figure L)
• Use your finger to gently push down on the plunger.
• When the plunger head is as far down as it will go, all of the GRANIX has been injected. When done, gently remove the needle from the skin.

**FIGURE K**

**Step 4E:** Throw away (dispose of) used needle and syringe
• Put your used needles and syringes in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and syringes in your household trash.
• If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
  - made of a heavy-duty plastic,
  - can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
  - upright and stable during use,
  - leak-resistant, and
  - properly labeled to warn of hazardous waste inside the container.
• When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal.

**FIGURE M**

**Step 4F:** Treat the injection site if needed and wash your hands.
If you see drops of blood at the injection site, you can press a cotton ball or gauze over the injection site for several seconds to stop the bleeding. Apply bandage, if needed.
When you are finished, wash your hands with soap and water (Figure M).

**FIGURE L**

**Step 4G:** Repeat steps 1E through 4F with a new vial of GRANIX if your healthcare provider instructs you that your dose is more than 1 vial.

If you have any questions or concerns about your dose of GRANIX or how to prepare and give your injections, call your healthcare provider. This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Manufactured by:
Sicor Biotech UAB
Vilnius, Lithuania
U.S. License No. 1803

Distributed by:
Teva Pharmaceuticals USA, Inc.
North Wales, PA 19454
Product of Israel

Revised: 07/2018
TBOIFUV-001
teva

©2014-2018 Cephalon, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. All rights reserved.
GRX-41244